These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1457 related items for PubMed ID: 16307708

  • 1. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [Abstract] [Full Text] [Related]

  • 2. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, Van der Bom JG, Jukema JW.
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [Abstract] [Full Text] [Related]

  • 3. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 4. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 5. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 6. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [Abstract] [Full Text] [Related]

  • 8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 9. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ, Gibson JM.
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, STELLAR Study Group.
    Curr Med Res Opin; 2003 May; 19(8):689-98. PubMed ID: 14687438
    [Abstract] [Full Text] [Related]

  • 11. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
    Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group.
    Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
    [Abstract] [Full Text] [Related]

  • 13. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group.
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [Abstract] [Full Text] [Related]

  • 14. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [Abstract] [Full Text] [Related]

  • 15. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group.
    Am J Cardiol; 2006 Sep 15; 98(6):768-73. PubMed ID: 16950182
    [Abstract] [Full Text] [Related]

  • 16. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 15; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.
    Am J Manag Care; 2006 Nov 15; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [Abstract] [Full Text] [Related]

  • 18. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
    Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W.
    Eur Heart J; 2005 Dec 15; 26(24):2664-72. PubMed ID: 16143705
    [Abstract] [Full Text] [Related]

  • 19. Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
    Jayaram S, Jain MM, Naikawadi AA, Gawde A, Desai A.
    J Indian Med Assoc; 2004 Jan 15; 102(1):48-50, 52. PubMed ID: 15195867
    [Abstract] [Full Text] [Related]

  • 20. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M, O'donnell J, Olsson A.
    Int J Cardiol; 2005 Oct 10; 104(3):251-6. PubMed ID: 16186052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.